ArticleBlood advances2018
Article in Blood advances, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- How to Read a Next-Generation Sequencing Report for AML and MDS? What Hematologists Need to Know.Journal of clinical medicine · 2025Review
- Validation Study of Analytical Methods for Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in Acute Myeloid Leukemia.International journal of molecular sciences · 2025Article
- Persistent postremission clonal hematopoiesis shapes the relapse trajectories of acute myeloid leukemia.Blood advances · 2025Article
- Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia.Bone marrow transplantation · 2025Review
- Pre-emptive therapeutic decisions based on measurable residual disease status in acute myeloid leukemia: ready for prime time?Leukemia · 2025Review
- Prognostic impact of clonal hematopoiesis mutations at complete molecular remission in acute myeloid leukemia with NPM1 mutation.Journal of cancer research and clinical oncology · 2024Article
- Early drivers of clonal hematopoiesis shape the evolutionary trajectories ofmedRxiv : the preprint server for health sciences · 2024Article
- Pre-emptive detection and evolution of relapse in acute myeloid leukemia by flow cytometric measurable residual disease surveillance.Leukemia · 2024Article
- Comprehensive insights into AML relapse: genetic mutations, clonal evolution, and clinical outcomes.Cancer cell international · 2024Article
- Article
- Myeloid neoplasm occurrence during stable molecular remission of NPM1-mutated AML: are we facing secondary disease or AML relapse?Blood cancer journal · 2023Article
- Article
- [Effect of clonal hematopoiesis in remission on hematopoiesis recovery in patients with NPM1 mutated acute myeloid leukemia after chemotherapy].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2023Article
- Genetic, Phenotypic, and Clinical Heterogeneity of NPM1-Mutant Acute Myeloid Leukemias.Biomedicines · 2023Review
- Novel Tools for Diagnosis and Monitoring of AML.Current oncology (Toronto, Ont.) · 2023Review
- Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML.Blood advances · 2023Article
- NPM 1 Mutations in AML-The Landscape in 2023.Cancers · 2023Review
- Pseudo-mutant P53 is a unique phenotype ofHaematologica · 2022Article
- The Role of Nucleophosmin 1 (Life (Basel, Switzerland) · 2022Review
- Leukemic Stem Cell: A Mini-Review on Clinical Perspectives.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute myeloid leukemia (AML) with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.